Gilead strikes voluntary licensing agreements with six generic manufacturers for lenacapavir but health groups seek clarity on pricing and seeming API supply restrictions. All eyes are also on the patent opposition case in India.

The next six years will see rapid growth in several newer pharmaceutical technology groups. In this article In Vivo examines the technologies currently forecast to see highest rates of growth, as well as those with the most actual sales growth out to 2030.

So far this year, when the agency has taken action on NMEs that went before advisory committees, the FDA decision has matched the committee vote.

Rytelo is a first-in-class telomerase inhibitor approved for the treatment of lower-risk myelodysplastic syndromes with transfusion-dependent anemia.